Literature DB >> 27183709

Caspase-3 activation in human melanoma A375 cell line by a novel selective sigma-2 agonist.

S Ronsisvalle, G Arico, A M Cova, P Blanco, E Amata, M Pappalardo, L Pasquinucci, A Spadaro, N Ronsisvalle.   

Abstract

Two novel 8-azabicyclo[3.2.1]octan-3-ol derivatives, 11a and 11b, with high affinity for sigma-2 receptors and a very good sigma-1/sigma-2 selectivity ratio were synthesized. In comparison with several well established sigma-2 selective ligands, 11 b showed a very low sigma-1 receptor affinity. Functional assays demonstrated that 11b acts as an agonist and in A-375 human melanoma cell line is able to lower levels of procaspase-3, thus confirming a potential major role for sigma-2 pure agonists in the treatment of rapid proliferating melanoma cells.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27183709

Source DB:  PubMed          Journal:  Pharmazie        ISSN: 0031-7144            Impact factor:   1.267


  3 in total

1.  Sigma-1 and Sigma-2 receptor ligands induce apoptosis and autophagy but have opposite effect on cell proliferation in uveal melanoma.

Authors:  Lucia Longhitano; Carlo Castruccio Castracani; Daniele Tibullo; Roberto Avola; Maria Viola; Giuliano Russo; Orazio Prezzavento; Agostino Marrazzo; Emanuele Amata; Michele Reibaldi; Antonio Longo; Andrea Russo; Nunziatina Laura Parrinello; Giovanni Li Volti
Journal:  Oncotarget       Date:  2017-07-25

2.  Sigma-2 receptor ligands QSAR model dataset.

Authors:  Antonio Rescifina; Giuseppe Floresta; Agostino Marrazzo; Carmela Parenti; Orazio Prezzavento; Giovanni Nastasi; Maria Dichiara; Emanuele Amata
Journal:  Data Brief       Date:  2017-06-16

3.  S2RSLDB: a comprehensive manually curated, internet-accessible database of the sigma-2 receptor selective ligands.

Authors:  Giovanni Nastasi; Carla Miceli; Valeria Pittalà; Maria N Modica; Orazio Prezzavento; Giuseppe Romeo; Antonio Rescifina; Agostino Marrazzo; Emanuele Amata
Journal:  J Cheminform       Date:  2017-01-21       Impact factor: 5.514

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.